Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reimportation Is "Phony" Issue, Waxman Says, But Driven By Real Pricing Problems

This article was originally published in The Pink Sheet Daily

Executive Summary

Reimportation is not the solution to high U.S. drug prices, Rep. Henry Waxman (D-Calif.) said

You may also be interested in...



Medicare Rx Formulary Design Should Prevent Risk Selection – Rep. Waxman

CMS faces a dilemma in trying to satisfy both plan providers and manufacturers, Waxman acknowledges, and says that the agency should ensure that formularies do not discourage use by high-cost beneficiaries.

Medicare Rx Formulary Design Should Prevent Risk Selection – Rep. Waxman

CMS faces a dilemma in trying to satisfy both plan providers and manufacturers, Waxman acknowledges, and says that the agency should ensure that formularies do not discourage use by high-cost beneficiaries.

Reimportation Law Unlikely This Year Despite Democratic Pressure

Senate Majority Leader Frist says he does not expect to fit Rx import language into the schedule during the session’s remaining days. The Senate Health Committee has no plans to markup a bill.

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel